Get started

Humana

Humana | HUM | Long at $220.00Humana NYSE:HUM took a nosedive to "crash" levels (based on my selected simple moving averages (SMA)) this morning after a lower-performance rating for a widely used Medicare insurance plan is expected to hurt enrollments for 2025 (and will potentially hit the health insurer's revenue and bonus payments in 2026). However, I view this massive drop as an opportunity for an initial long entry for a great value stock. The company is strong, highly rated among patients, and solid fundamentals despite the anticipated earnings drop. From a technical analysis perspective, it touched my "crash" SMA, but may dip further after a dead cat bounce to the $190s in the coming days or weeks. But, predicting true bottom is a fool's game, so at $220.00, NYSE:HUM is in a personal buy zone for an initial long entry. Target #1 = $250.00 Target #2 = $275.00 Target #3 = $314.00 Target #4 = $340.00
NYSE:HUMLong
by WorthlessViews
HUM Slide 14.67% Amidst Increase in Medicare Advantage PlansHumana's ( NYSE:HUM ) stock has experienced a significant decline of almost 15% in early trading on Tuesday, following the Centers for Medicare & Medicaid Services (CMS) announcement of a 3.7% increase in federal payments to Medicare Advantage plans. This increase matches the percentage increase proposed in January, leading to disappointment among investors and concerns regarding health insurers' profit margins, given the rising costs of medical care. The CMS has projected that the federal government will contribute between $500 billion and $600 billion in Medicare Advantage payments to private health plans in 2025, to maintain the stability of the program and ensure that payments are up-to-date and accurate. Humana's CFO, Susan Diamond, had previously informed investors that the health insurer would fall short of its upper earnings-per-share growth target without a more significant increase in payments. The payment revision, which excludes the estimated growth in patient risk scores, represents a 0.16% decline, leading to disappointment among investors and health insurers who had lobbied for a higher increase. Research from JPMorgan cited by Bloomberg revealed that there has only been one instance in the past decade where Medical Advantage plan final rates have not increased from the government's initial rate proposals. Other health insurers, including CVS Health, UnitedHealth Group, and Centene, have also experienced declines following the news, losing 5.9%, 4.5%, and 2.3%, respectively, in after-hours trading. However, Humana has been hit the hardest, with the stock falling 14.65% to $299.70 in early morning trading on Tuesday, putting it at levels not seen since the early days of the pandemic in March 2020. Technical Outlook With the Relative Strength Index (RSI) at 20 a break below the ceiling of the falling wedge is imminent thereby forming a new support at that level and spike after any major fundamentals. Allowing buyers to stack at that level. Investors should keep an eye on a key horizontal trendline that stretches back to the stock's April 2020 pandemic recovery, an area that may attract buying interest around $318, amid Tuesday's expected news-driven sell-off to a multi-year low.
NYSE:HUMShort
by DEXWireNews
Humana's Stock Plunges But shows Signs of a Reverse Trend Humana Inc., ( NYSE:HUM ) the second-largest Medicare Advantage company in the U.S., has sent shockwaves through the health insurance sector by revising its earnings guidance for 2025 and projecting 2024 profits well below analysts' expectations. The stock plummeted as much as 15%, marking the most significant intraday drop since June. This unexpected development has ignited concerns about the profitability of private Medicare plans and their potential impact on seniors' healthcare costs. The Medicare Advantage Dilemma: Humana's grim outlook stems from challenges faced by private Medicare plans, which have been a significant source of growth for health insurers in recent years. Rising medical costs are forcing Humana ( NYSE:HUM ) to consider raising prices and reducing benefits to maintain profit margins. Executives revealed on a conference call that this move may trigger a broader industry repricing of plans in the upcoming year, potentially signaling the end of the Medicare Advantage boom. Industry-Wide Ripple Effect: Humana's forecast has not only impacted its own stock but has also led to a sector-wide sell-off. Competitors such as UnitedHealth Group Inc., Cigna Group, CVS Health Corp., and Centene Corp. experienced substantial declines in their stock prices. The reasons behind the surge in medical costs vary among insurers, adding uncertainty to the already turbulent sector. Regulatory Changes and Emerging Trends: Several factors contribute to the challenging landscape for health insurers. The U.S. government's proposed changes to payment rates and plans to recoup past overpayments are colliding with an increase in medical costs as patients resume deferred care from the pandemic. These changes are being phased in over the next three years, creating additional pressure on insurers. Humana's Long-Term Prospects: The revised earnings guidance suggests a significant setback for Humana, as the projected adjusted earnings for 2024 are expected to be around $16 per share, a level not seen since 2018. Analysts express surprise and skepticism about the company's growth plans, with some doubting the feasibility of achieving a $6 to $10 per share growth in 2025. Market Reaction and Investor Concerns: Humana's dismal performance has ignited concerns among investors about the broader health insurance industry. Analysts are questioning whether the company can return to its long-term multiple and express concerns about slowing demographic trends in the 65+ market, which are expected to moderate in the second half of the 2020s. Conclusion: Humana's unexpected downturn serves as a stark reminder of the challenges facing health insurers, particularly those heavily invested in Medicare Advantage plans. The industry is at a crossroads, navigating regulatory changes, surging medical costs, and an uncertain economic landscape. Investors will be closely watching how competitors respond to these challenges and whether the Medicare Advantage boom is indeed coming to an end.
NYSE:HUMLong
by DEXWireNews
Humana to find buyers at previous support?Humana Inc - 30d expiry - We look to Buy at 480.48 (stop at 468.48) The primary trend remains bullish. Bespoke support is located at 480. Preferred trade is to buy on dips. A break of the recent high at 503.52 should result in a further move higher. We look to buy dips. 478.40 has been pivotal. Our profit targets will be 510.48 and 518.48 Resistance: 503.52 / 510.00 / 515.00 Support: 486.60 / 479.35 / 470.00 Please be advised that the in formation presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Everest Fortune Group’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Everest Fortune Group
NYSE:HUMLong
by VantageMarkets
Humana to find buyers at previous support?Humana Inc - 30d expiry - We look to Buy at 481.11 (stop at 468.38) Price action continued to range between key support & resistance (480 - 515) although we expect a break of this range soon. The primary trend remains bullish. We look to buy dips. Short term momentum is bearish. We look for a temporary move lower. Our profit targets will be 512.88 and 518.88 Resistance: 500 / 510 / 515 Support: 495 / 490 / 480 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NYSE:HUMLong
by VantageMarkets
Humana ranging between key support and resistance.Humana Inc - 30d expiry - We look to Buy at 481.11 (stop at 468.38) Price action continued to range between key support & resistance (480 - 515) although we expect a break of this range soon. The primary trend remains bullish. We look to buy dips. We look for a temporary move lower. Expect trading to remain mixed and volatile. Our profit targets will be 512.88 and 518.88 Resistance: 514 / 515 / 528 Support: 500 / 490 / 480 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NYSE:HUMLong
by VantageMarkets
HUM: Test previous lows?Humana Inc Short Term - We look to Sell a break of 480.38 (stop at 489.09) Short term momentum is bearish. Daily/Weekly Ichimoku Cloud resistance is seen at 488. Further downside is expected. A break of 480.00 is needed to confirm follow through negative momentum. Our profit targets will be 455.29 and 440.00 Resistance: 500.00 / 520.00 / 580.00 Support: 480.00 / 450.00 / 400.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’) . Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NYSE:HUMShort
by VantageMarkets
$HUM Humana LT Chart - LEAP OptionsHumana fairly rangebound for the last six months. Tested ~$470 key resistance level six times unsuccessfully. Monitor for a breakthrough and close above this level. Once this occurs we could see an overdue strong move to the $600 area by 1H of 2024. Long Term Target: $580-$615 range by 1H '24 I plan to play this using LEAP options. I'm looking at the $450 and $500 Jan'24 calls. If you're looking to limit risk and capital outlay, I would consider a vertical call spread buying either the $450 or $500 call and selling the $600. Note: This is NOT investment advice. This is opinion only.
NYSE:HUMLong
by Triple_Barrel_Capital
Time For Humana To Naturally Cycle DownHumana Inc has been in a clearly defined bullish trend since July 2016. As of the close on May 15, this stock is at the top of the cycle which is near a strongly established resistance line. The projected future movements are highlighted below. When we take a look at other technical indicators, the relative strength index (RSI) is at 73.8915. RSI tends to determine trends, overbought and oversold levels as well as likelihood of price swings. I personally use anything above 75 as overbought and anything under 25 as oversold. Currently the RSI is just beginning to exit overbought territory and should encourage the stock to move bearishly down. The true strength index (TSI) is currently 34.8840. The TSI determines overbought/oversold levels and/or current trend. I solely use this as an indicator of trend as overbought and oversold levels vary. The TSI is double smoothed in its calculation and is a great indicator of upward and downward movement. The current reading declares the stock has been moving up. The positive vortex indicator (VI) is at 1.2844 and the negative is at 0.7283. When the positive level is higher than 1 and higher than the negative indicator, the overall price action is moving upward. When the negative level is higher than 1 and higher than the positive indicator, the overall price action is moving downward. Currently the positive indicator had been moving up, but the upward action is slowing. The stock should begin to move down and the positive and negative indicators will begin to move closer together. The stochastic oscillator K value is 85.7857 and D value is 88.5560. This is a cyclical oscillator that is highly accurate and can be used to identify overbought/oversold levels as well as pending reversals and short-term activity. I personally use anything above 80 as overbought and below 20 as oversold. When the K value is higher than the D value, the stock is trending up. When the D value is higher that the K value the stock is trending down. The stochastic is currently in overbought territory and the D is above the K value meaning the stock should begin to fall. A similar pattern with volume occurred in December 2016. The stock moved up on greater than average volume for 4 days in a row before the stock began to sell off on greater than average volume. The same thing occurred on May 15. During this sell off in December, the stock sold off around 10% over the next 20 trading days. Even though something like this is possible right now, I conservatively believe the stock will hold to its white-dotted trendline which is a drop of at least 4%. Considering the RSI, TSI, VI and stochastic levels, the overall direction favors a move to the downside, although definitive downward movement may take a few more days to develop. Based on historical movement compared to current levels and the current position, the stock could drop at least 4% over the next 33 trading days if not sooner. More at LimitLessLifeSkills!
NYSE:HUMShort
by StockSignaler